Cargando…

Response and Resistance to MEK Inhibition in Leukaemias Initiated by Hyperactive Ras

The Raf/MEK/ERK cascade is a therapeutic target in human cancers with deregulated Ras signaling, which includes tumours that have inactivated the Nf1 tumour suppressor(1). Nf1 encodes neurofibromin, a GTPase activating protein that terminates Ras signalling by stimulating hydrolysis of Ras•GTP. We c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lauchle, Jennifer O., Kim, Doris, Le, Doan T., Akagi, Keiko, Crone, Michael, Krisman, Kimberly, Warner, Kegan, Bonifas, Jeannette M., Li, Qing, Coakley, Kristin M., Diaz-Flores, Ernesto, Gorman, Matthew, Przybranowski, Sally, Tran, Mary, Kogan, Scott C., Roose, Jeroen P., Copeland, Neal, Jenkins, Nancy, Parada, Luis, Wolff, Linda, Sebolt-Leopold, Judith, Shannon, Kevin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2009
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4119783/ https://www.ncbi.nlm.nih.gov/pubmed/19727076 http://dx.doi.org/10.1038/nature08279

Ejemplares similares

MEK targeting in N-RAS mutated metastatic melanoma
por: Thumar, Jaykumar, et al.
Publicado: (2014)

Polymorphisms in RAS/RAF/MEK/ERK Pathway Are Associated with Gastric Cancer
por: Gonzalez-Hormazabal, Patricio, et al.
Publicado: (2018)

Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy
por: Degirmenci, Ufuk, et al.
Publicado: (2020)

EZH2 inactivation in RAS-driven myeloid neoplasms hyperactivates RAS-signaling and increases MEK inhibitor sensitivity
por: Berg, Johannes Lorenz, et al.
Publicado: (2021)

Regulation of Ras Exchange Factors and Cellular Localization of Ras Activation by Lipid Messengers in T Cells
por: Jun, Jesse E., et al.
Publicado: (2013)

Targeted elimination of senescent Ras-transformed cells by suppression of MEK/ERK pathway
por: Kochetkova, Elena Y., et al.
Publicado: (2017)

Efficacy of MEK inhibition in a K-Ras-driven cholangiocarcinoma preclinical model
por: Dong, Mingjie, et al.
Publicado: (2018)

Correlation between MEK signature and Ras gene alteration in advanced gastric cancer
por: Ahn, Soomin, et al.
Publicado: (2017)

Combined targeting of MEK and the glucocorticoid receptor for the treatment of RAS-mutant multiple myeloma
por: Sriskandarajah, Priya, et al.
Publicado: (2020)

Sensitivity and Resistance of Oncogenic RAS-Driven Tumors to Dual MEK and ERK Inhibition
por: Catalano, Antonella, et al.
Publicado: (2021)

Reusability and composability in process description maps: RAS–RAF–MEK–ERK signalling
por: Mazein, Alexander, et al.
Publicado: (2021)

Reversal of the Ras-Induced Transformed Phenotype by Hr12, a Novel Ras Farnesylation Inhibitor, Is Mediated by the Mek/ERK Pathway
por: Reuveni, Hadas, et al.
Publicado: (2000)

Modulation of the Akt/Ras/Raf/MEK/ERK pathway by A(3) adenosine receptor
por: Merighi, Stefania, et al.
Publicado: (2006)

The Ras/Raf/MEK/ERK signaling pathway and its role in the occurrence and development of HCC
por: Li, Lei, et al.
Publicado: (2016)

Enhancement of Cancer-Specific Protoporphyrin IX Fluorescence by Targeting Oncogenic Ras/MEK Pathway
por: Yoshioka, Ema, et al.
Publicado: (2018)

RDM1 promotes neuroblastoma growth through the RAS–Raf–MEK–ERK pathway
por: Xie, Guojin, et al.
Publicado: (2019)

Onco-immunomodulatory properties of pharmacological interference with RAS-RAF-MEK-ERK pathway hyperactivation
por: Avery, Thomas Yul, et al.
Publicado: (2022)

Targeting RAS Mutant Colorectal Cancer with Dual Inhibition of MEK and CDK4/6
por: Sorokin, Alexey V., et al.
Publicado: (2022)

CREBBP knockdown enhances RAS/RAF/MEK/ERK signaling in Ras pathway mutated acute lymphoblastic leukemia but does not modulate chemotherapeutic response
por: Dixon, Zach A., et al.
Publicado: (2017)

Roles of the PI-3K and MEK pathways in Ras-mediated chemoresistance in breast cancer cells
por: Jin, W, et al.
Publicado: (2003)

Mek1/2 Gene Dosage Determines Tissue Response to Oncogenic Ras Signaling in the Skin
por: Scholl, F A, et al.
Publicado: (2009)

The MEK-ERK Pathway Is Necessary for Serine Phosphorylation of Mitochondrial STAT3 and Ras-Mediated Transformation
por: Gough, Daniel J., et al.
Publicado: (2013)

IRF1 Downregulation by Ras/MEK Is Independent of Translational Control of IRF1 mRNA
por: Komatsu, Yumiko, et al.
Publicado: (2016)

Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors
por: Merchant, Mark, et al.
Publicado: (2017)

Molecular signaling in multiple myeloma: association of RAS/RAF mutations and MEK/ERK pathway activation
por: Xu, J, et al.
Publicado: (2017)

RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K‐RAS mutant tumors
por: Yuan, Xi, et al.
Publicado: (2020)

A RAS-Independent Biomarker Panel to Reliably Predict Response to MEK Inhibition in Colorectal Cancer
por: Pfohl, Ulrike, et al.
Publicado: (2022)

CRISPR/Cas9 Edited RAS & MEK Mutant Cells Acquire BRAF and MEK Inhibitor Resistance with MEK1 Q56P Restoring Sensitivity to MEK/BRAF Inhibitor Combo and KRAS G13D Gaining Sensitivity to Immunotherapy
por: Turner, Elizabeth, et al.
Publicado: (2022)

Structural analysis of autoinhibition in the Ras-specific exchange factor RasGRP1
por: Iwig, Jeffrey S, et al.
Publicado: (2013)

PI3 kinase is important for Ras, MEK and Erk activation of Epo-stimulated human erythroid progenitors
por: Schmidt, Enrico K, et al.
Publicado: (2004)

Ras/Raf/MEK/ERK Pathway Activation in Childhood Acute Lymphoblastic Leukemia and Its Therapeutic Targeting
por: Knight, Thomas, et al.
Publicado: (2014)

Correction: The MEK-ERK Pathway Is Necessary for Serine Phosphorylation of Mitochondrial STAT3 and Ras-Mediated Transformation
por: Gough, Daniel J., et al.
Publicado: (2013)

Correction: Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors
por: Merchant, Mark, et al.
Publicado: (2018)

SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers
por: Jones, Greg G., et al.
Publicado: (2019)

RAS activation induces synthetic lethality of MEK inhibition with mitochondrial oxidative metabolism in acute myeloid leukemia
por: Decroocq, Justine, et al.
Publicado: (2022)

P342: RAS PATHWAY ACTIVATION REMODELS THE BONE MARROW MICROENVIRONMENT IN ACUTE LYMPHOBLASTIC LEUKAEMIA
por: Ferrao Blanco, Mauricio, et al.
Publicado: (2023)

Mutant K-ras oncogene regulates steroidogenesis of normal human adrenocortical cells by the RAF-MEK-MAPK pathway
por: Wu, C-H, et al.
Publicado: (2002)

Aurora-A overexpression enhances cell-aggregation of Ha-ras transformants through the MEK/ERK signaling pathway
por: Tseng, Ya-Shih, et al.
Publicado: (2009)

RAS/RAF/MEK/ERK and PI3K/PTEN/AKT Signaling in Malignant Melanoma Progression and Therapy
por: Yajima, Ichiro, et al.
Publicado: (2012)

Suppression of IFN-Induced Transcription Underlies IFN Defects Generated by Activated Ras/MEK in Human Cancer Cells
por: Christian, Sherri L., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_sohck9910dr82aaegmp5k1564v